Essex Bio-Technology (SEHK:1061) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

1061 Overzicht aandelen

Essex Bio-Technology Limited, een investeringsholding, ontwikkelt, produceert, distribueert en verkoopt biofarmaceutische producten in de Volksrepubliek China, Hongkong en internationaal.

Over het bedrijf

1061 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	3/6
Financiële gezondheid	6/6
Dividenden	4/6

Beloningen

De koers-winstverhouding ( 5.8 x) ligt onder de Hong Kong markt ( 10 x)

De winst is de afgelopen 5 jaar met 0.01% per jaar gegroeid

Risicoanalyse

Onstabiel dividend track record

Essex Bio-Technology Limited Concurrenten

Uni-Bio Science Group

SEHK:690

HK$466.4m

Shandong Boan Biotechnology

SEHK:6955

HK$5.4b

TOT BIOPHARM International

SEHK:1875

HK$1.5b

HBM Holdings

SEHK:2142

HK$1.1b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Essex Bio-Technology
Historische aandelenkoersen
Huidige aandelenkoers	HK$2.70
52 Week Hoogtepunt	HK$2.95
52 Week Laag	HK$1.96
Bèta	0.20
11 maand verandering	14.89%
3 maanden verandering	12.97%
1 Jaar Verandering	-3.91%
33 jaar verandering	-51.87%
5 jaar verandering	-47.06%
Verandering sinds IPO	172.73%

Recent nieuws en updates

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

Aug 29

Recent updates

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

Aug 29

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

May 02

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Mar 30

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Jun 29

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Mar 31

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Mar 13

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Jan 25

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 04

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 13

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Nov 23

Rendement voor aandeelhouders

	1061	HK Biotechs	HK Markt
7D	17.9%	18.3%	8.7%
1Y	-3.9%	1.9%	19.7%

Rendement versus industrie: 1061 presteerde slechter dan de Hong Kong Biotechs -sector, die het afgelopen jaar een rendement van 1.9 % opleverde.

Rendement versus markt: 1061 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 19.7 % opleverde.

Prijsvolatiliteit

Is 1061's price volatile compared to industry and market?
1061 volatility
1061 Average Weekly Movement	5.2%
Biotechs Industry Average Movement	7.8%
Market Average Movement	7.1%
10% most volatile stocks in HK Market	14.7%
10% least volatile stocks in HK Market	3.6%

Stabiele aandelenkoers: 1061 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van 1061 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1990	1,459	Haizhou Fang	www.essexbio.com

Essex Bio-Technology Limited, een investeringsholding, ontwikkelt, produceert, distribueert en verkoopt biofarmaceutische producten in de Volksrepubliek China, Hongkong en internationaal. Het bedrijf is actief in de segmenten Oogheelkunde en Chirurgie. Het onderzoekt en ontwikkelt therapeutische fibroblastgroeifactorproducten voor de behandeling van celproliferatie, differentiatie en migratie.

Essex Bio-Technology Limited Samenvatting

Hoe verhouden de winst en inkomsten van Essex Bio-Technology zich tot de beurswaarde?
1061 fundamentele statistieken
Marktkapitalisatie	HK$1.53b
Inkomsten(TTM)	HK$262.89m
Inkomsten(TTM)	HK$1.62b

5.8x

Koers/Winstverhouding

0.9x

P/S-verhouding

Is 1061 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
1061 resultatenrekening (TTM)
Inkomsten	HK$1.62b
Kosten van inkomsten	HK$165.38m
Brutowinst	HK$1.45b
Overige uitgaven	HK$1.19b
Inkomsten	HK$262.89m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.46
Brutomarge	89.78%
Nettowinstmarge	16.24%
Schuld/Eigen Vermogen Verhouding	15.2%

Hoe presteerde 1061 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

4.4%

Huidig dividendrendement

23%

Uitbetalingsratio

1061 Overzicht aandelen

Beloningen

Risicoanalyse

Essex Bio-Technology Limited Concurrenten

SEHK:690

HK$466.4m

SEHK:6955

HK$5.4b

SEHK:1875

HK$1.5b

SEHK:2142

HK$1.1b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Investor sentiment improves as stock rises 19%

First half dividend increased to HK$0.06

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

First half 2024 earnings released: EPS: HK$0.28 (vs HK$0.30 in 1H 2023)

Essex Bio-Technology Limited to Report First Half, 2024 Results on Aug 26, 2024

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023

Recent updates

Investor sentiment improves as stock rises 19%

First half dividend increased to HK$0.06

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

First half 2024 earnings released: EPS: HK$0.28 (vs HK$0.30 in 1H 2023)

Essex Bio-Technology Limited to Report First Half, 2024 Results on Aug 26, 2024

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.045 per share

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Now 21% overvalued

Now 22% overvalued

Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Essex Bio-Technology Limited to Report Fiscal Year 2023 Results on Mar 18, 2024

Investor sentiment deteriorates as stock falls 16%

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Upcoming dividend of HK$0.045 per share at 2.0% yield

First half 2023 earnings released: EPS: HK$0.30 (vs HK$0.24 in 1H 2022)

Essex Bio-Technology Limited to Report First Half, 2023 Results on Aug 16, 2023

Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative (Wet) Age-Related Macular Degeneration

Less than half of directors are independent

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.025 per share at 1.8% yield

Now 21% undervalued after recent price drop

Essex Bio-Technology Limited Completes First Patient First Dose in the United States in an International Multi-Centre Phase 3 Clinical Study

Essex Bio-Technology Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Price target decreased to HK$6.00

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Upcoming dividend of HK$0.04 per share

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

First half 2022 earnings released: EPS: HK$0.24 (vs HK$0.28 in 1H 2021)

Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on September 21, 2022

Essex Bio-Technology Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021

Price target increased to HK$7.00

Less than half of directors are independent

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.04 per share

First half 2021 earnings released: EPS HK$0.28 (vs HK$0.085 in 1H 2020)

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021 at the Annual General Meeting held on May 12, 2021

Upcoming dividend of HK$0.05 per share

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Essex Bio-Technology Limited Announces Dividend for the Year Ended December 31, 2020, Payable on 1 June 2021

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Essex Bio-Technology Limited, Annual General Meeting, May 12, 2021

Full year 2020 earnings released: EPS HK$0.38 (vs HK$0.52 in FY 2019)

Essex Bio-Technology Limited to Report Fiscal Year 2020 Results on Mar 12, 2021